GPCR標的治療薬 - 標的集団、競合情勢、市場予測（2034年）

主なハイライト

• 多くの腫瘍でGPCRが過剰発現していることから、GPCRは一般的な腫瘍から希少な腫瘍まで、幅広いがんの適応症において有効な標的となります。
• GPCR標的治療薬は、末梢性T細胞リンパ腫（PTCL）や皮膚T細胞リンパ腫（CTCL）、菌状息肉症やセザリー症候群のようなタイプの治療に不可欠であり、片頭痛治療薬としても承認されています。さらに、HIV-NASH（非アルコール性脂肪性肝炎）や糖尿病の治療薬としても開発中です。
• POTELIGEO、AIMOVIG、ZAVZPRETが、GPCR標的治療薬として承認されています。
• 2023年3月、米国FDAはPfizerのZAVZPRET（zavegepant）を承認し、前兆の有無にかかわらず成人の片頭痛の急性期治療薬として最初で唯一のカルシトニン遺伝子関連ペプチド（CGRP）受容体拮抗点鼻薬としました。
• VYEPTIは、成人の片頭痛発症の予防に使用される治療薬です。片頭痛の誘発に重要な役割を果たすタンパク質であるCGRPの活性を阻害することにより作用します。
• GSBR-1290は、肥満症と2型糖尿病の治療薬として開発されたGLP-1受容体作動薬です。バイアスGPCRアゴニストとして設計されており、B-アレスチン経路を誘発することなく、Gタンパク質シグナル伝達経路を選択的に活性化します。
• 2023年12月、CytoDynはAlbert Einstein College of MedicineおよびMontefiore Medical Centerと提携し、致死的な脳腫瘍である膠芽腫に対するleronlimabの有効性を評価する前臨床試験を実施しました。
• 2024年7月、Radionetics OncologyはEli Lillyと戦略的契約を締結し、Radionetics独自のGPCR標的低分子放射性医薬品へのアクセスをLillyに提供しました。
• CytoDyn、REMD Biotherapeutics、Structure Therapeutics、GPCR Therapeuticsなどの企業がGPCR標的治療薬法の開発に取り組んでいます。
• 2027年、米国が主要7市場の中でGPCR阻害薬市場全体の最大のシェアを占めると予測されます。

GPCR標的治療薬市場の見通し

GPCR標的治療薬市場は、今後数年間で大きく成長すると予測されます。これは、がんと診断される患者数の増加、GPCR標的治療薬に対する認知度の向上、各社が臨床試験中や承認申請中のGPCR標的治療薬の増加などによるものます。

GPCR標的治療薬市場の見通しは、ZAVZPRET、POTELIGEO、AIMOVIG、VYEPTIのような成功した医薬品により、有望です。Kyowa Hakko Kirinが開発し、POTELIGEOとして開発されているMogamulizumabは、CCR4受容体を標的とし、CCR4陽性の成人T細胞白血病、末梢性T細胞リンパ腫、皮膚T細胞リンパ腫の治療に有効であることが証明されています。AmgenとNovartisが開発したAIMOVIG（erenumab）は、CGRP受容体を標的とし、片頭痛、血管収縮、ほてり、安定狭心症に使用されており、GPCR標的治療薬の特異性と有効性を示しています。VYEPTIはFDAが承認した片頭痛予防向けの点滴治療薬です。

VolagidemabやLeronlimab、GPC-100、GSBR-1290といった新治療薬は、この市場の拡大する可能性を浮き彫りにしています。抗グルカゴン受容体抗体であるVolagidemabは、グルカゴン受容体シグナル伝達を遮断することで低血糖を促進するもので、I型とII型の糖尿病を対象にフェーズII試験中です。Leronlimabは、CCR5受容体を標的とするウイルス侵入阻害薬で、HIV、非アルコール性脂肪性肝炎（NASH）、HIV-NASH、固形がんを対象にフェーズII開発中です。これらの進歩は、さまざまな疾患におけるGPCR標的薬の大きな治療可能性と市場機会を示しています。

当レポートでは、GPCR標的治療薬の主要7市場（米国、ドイツ、スペイン、イタリア、フランス、英国、日本）について調査分析し、各地域の市場規模、現在の治療法、アンメットニーズ、新薬などの情報を提供しています。

目次

第1章 主な調査結果

第2章 レポートのイントロダクション

第3章 GPCR標的治療薬のエグゼクティブサマリー

第4章 主な出来事

第5章 疫学と市場予測の調査手法

第6章 主要7市場のGPCR標的治療薬市場の概要

• 市場シェアの分布：適応症別（2020年）
• 市場シェアの分布：適応症別（2034年）

第7章 GPCR標的治療薬：背景と概要

第8章 治療と管理

第9章 標的患者集団

• 主な調査結果
• 前提条件と根拠：主要7市場
• 主要7市場の疫学シナリオ
  • 主要7市場のGPCR標的治療薬の適応症の総患者数
  • 主要7市場のGPCR標的治療薬の適応症における総患者集団
  • 主要7市場のGPCR標的治療薬の適応症における治療可能な総患者数

第10章 上市済みの治療法

• 主な競合
• POTELIGEO（mogamulizumab-kpkc）：Kyowa Hakko Kirin
• AIMOVIG（erenumab-aooe）：Novartis/Amgen

第11章 新治療法

• 主な競合
• Volagidemab：REMD Biotherapeutics
• Leronlimab：CytoDyn

第12章 GPCR標的治療薬：主要7市場の分析

• 主な調査結果
• 市場見通し
• コンジョイント分析
• 主な市場予測の前提条件
  • コストの想定とリベート
  • 価格動向
  • アナログの評価
  • 上市年と治療の普及
• 主要7市場の市場規模：適応症別
• 主要7市場の市場規模：治療法別
• 米国
  • 米国の市場規模：適応症別
  • 米国の市場規模：治療法別
• 欧州4ヶ国・英国
  • 欧州4ヶ国・英国の市場規模：適応症別
  • 欧州4ヶ国・英国の市場規模：治療法別
• 日本
  • 日本の市場規模：適応症別
  • 日本の市場規模：治療法別

第13章 KOLの見解

第14章 アンメットニーズ

第15章 市場参入と償還

第16章 付録

第17章 DelveInsightのサービス内容

第18章 免責事項

第19章 DelveInsightについて

List of Tables

• Table 1: Target Population in the 7MM (2020-2034)
• Table 2: Marketed Drug Key cross
• Table 3: Product 1, Clinical Trial Description, 2024
• Table 4: Product 2, Clinical Trial Description, 2024
• Table 5: Emerging Drug Key cross
• Table 6: Product 1, Clinical Trial Description, 2024
• Table 7: Product 2, Clinical Trial Description, 2024
• Table 8: Total GPCR-Targeting Therapies Market Size in the 7MM (2020-2034)
• Table 9: GPCR-Targeting Therapies Market Size by Therapies in the 7MM (2020-2034)
• Table 10: GPCR-Targeting Therapies Market Size by Indication in the 7MM (2020-2034)
• Table 11: Total GPCR-Targeting Therapies Market Size in the United States (2020-2034)
• Table 12: GPCR-Targeting Therapies Market Size by Therapies in the United States (2020-2034)
• Table 13: Total GPCR-Targeting Therapies Market Size in EU4 and the UK (2020-2034)
• Table 14: GPCR-Targeting Therapies Market Size by Therapies in EU4 and the UK (2020-2034)
• Table 15: Total GPCR-Targeting Therapies Market Size in Japan (2020-2034)
• Table 16: GPCR-Targeting Therapies Market Size by Therapies in Japan (2020-2034)

List of Figures

• Figure 1: Target Population in the 7MM (2020-2034)
• Figure 2: Total GPCR-Targeting Therapies Market Size in the 7MM (2020-2034)
• Figure 3: GPCR-Targeting Therapies Market Size by Therapies in the 7MM (2020-2034)
• Figure 4: GPCR-Targeting Therapies Market Size by Indication in the 7MM (2020-2034)
• Figure 5: Total GPCR-Targeting Therapies Market Size in the United States (2020-2034)
• Figure 6: GPCR-Targeting Therapies Market Size by Therapies in the United States (2020-2034)
• Figure 7: Total GPCR-Targeting Therapies Market Size in EU4 and the UK (2020-2034)
• Figure 8: GPCR-Targeting Therapies Market Size by Therapies in EU4 and the UK (2020-2034)
• Figure 9: Total GPCR-Targeting Therapies Market Size in Japan (2020-2034)
• Figure 10: GPCR-Targeting Therapies Market Size by Therapies in Japan (2020-2034)

Key Highlights:

• The overexpression of GPCR in many tumors makes them a viable target for a wide range of cancer indications, spanning from common to rare tumors.
• GPCR-targeting therapies are crucial for treating Peripheral T-Cell Lymphoma (PTCL), Cutaneous T-Cell Lymphomas (CTCL) and their types such as mycosis fungoides, and sezary syndrome, and are also approved for migraine treatment. Additionally, they are being developed for HIV-NASH (Nonalcoholic Steatohepatitis) and diabetes.
• POTELIGEO, AIMOVIG, and ZAVZPRET are among the approved therapies that act by targeting GPCRs.
• In March 2023, the US FDA approved Pfizer ZAVZPRET (zavegepant), marking it as the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults.
• VYEPTI is a treatment used to help prevent migraine episodes in adults. It works by blocking the activity of CGRP, a protein that plays a key role in triggering migraines.
• GSBR-1290 is a GLP-1 receptor agonist developed to treat obesity and type 2 diabetes. Designed as a biased GPCR agonist, it selectively activates the G-protein signaling pathway without triggering B-arrestin pathways.
• In December 2023, CytoDyn partnered with Albert Einstein College of Medicine and Montefiore Medical Center to conduct pre-clinical trials evaluating leronlimab effectiveness against glioblastoma, a deadly brain cancer.
• In July 2024, Radionetics Oncology entered into a strategic agreement with Eli Lilly and Company providing Lilly access to Radionetics' proprietary GPCR targeting small molecule radiopharmaceuticals.
• Companies including CytoDyn, REMD Biotherapeutics, Structure Therapeutics, and GPCR Therapeutics are engaged in the development of GPCR-targeting therapies.
• In 2027, the United States is expected to hold the largest share of the total GPCR Inhibitors market among the 7MM.

DelveInsight's "GPCR-Targeting therapies - Target Population, Competitive Landscape, and Market Forecast - 2034" report delivers an in-depth understanding of the GPCR-targeting therapies, historical and competitive landscape as well as the GPCR-targeting therapies market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The GPCR-targeting therapies market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM GPCR-targeting therapies market size from 2020 to 2034. The report also covers current GPCR-targeting therapies treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

GPCR-Targeting Therapies Understanding

GPCR-Targeting Therapies Overview

G protein-coupled receptors (GPCRs) are important classes of cell surface receptors involved in multiple physiological functions. Aberrant expression, upregulation, and mutation of GPCR signaling pathways are frequent in many types of cancers, promoting hyperproliferation, angiogenesis, and metastasis. GPCRs are classified into several types based on their sequence and function: the main classes in humans are Class A (Rhodopsin-like), Class B (Secretin and Adhesion), Class C (Metabotropic glutamate/pheromone), and Class F (Frizzled/TAS2), with additional classes D (fungal mating pheromone receptors) and E (cyclic AMP receptors) found in other organisms. Class A is the largest group, including most hormone, neurotransmitter, and sensory receptors, while Class B is divided into secretin and adhesion subfamilies, Class C includes glutamate and GABA receptors, and Class F covers frizzled and smoothened receptors involved in Wnt signaling. This classification reflects the structural diversity and wide-ranging functions of GPCRs in health and disease.

Currently, GPCR-targeting therapies are approved for treating conditions such as PTCL, migraine, CTCL, and their types such as sezary syndrome (SS) and mycosis fungoides. They are also being developed for Nonalcoholic Steatohepatitis (NASH), HIV-NASH, solid tumors, and both Type I and Type II diabetes mellitus.

GPCR-Targeting therapies Epidemiology

The GPCR-targeting therapies epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total cases of selected indication for GPCR-targeting therapies, total eligible patient pool for GPCR-Targeting therapies in selected indication, total treated cases in selected indication for GPCR-targeting therapies in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.

• The total incident cases of cutaneous T-cell lymphomas in the 7MM comprised around 3,700 cases in 2024.
• Among EU4 and the UK, Germany had the highest incidence cases of cutaneous T-cell lymphoma, followed by France. On the other hand, Spain had the lowest incident Cases in 2024.
• In 2024, gender-specific cutaneous T-cell lymphoma cases for males and females accounted for approximately 1,950 and 1,700 cases in the United States.
• The total incident population of PTCL in Japan was ~8,500 in 2024.

GPCR-Targeting Therapies Drug Chapters

The drug chapter segment of the GPCR-targeting therapies reports encloses a detailed analysis of GPCR-targeting therapies-marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also helps understand the GPCR-targeting therapies' clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

ZAVZPRET (zavegepant): Pfizer

ZAVZPRET is a novel, small-molecule CGRP receptor antagonist approved for the acute treatment of migraine with or without aura in adults. ZAVZPRET blocks the CGRP receptor, which is implicated in migraine pathophysiology by mediating neurogenic inflammation and vasodilation. ZAVZPRET is formulated as a nasal spray, enabling rapid absorption through the nasal mucosa and direct entry into the bloodstream, bypassing gastrointestinal absorption and first-pass metabolism.

POTELIGEO (mogamulizumab-kpkc): Kyowa Hakko Kirin

POTELIGEO is a humanized monoclonal antibody developed by Kyowa Kirin that targets chemokine receptor 4 (CCR4), a protein frequently expressed on certain cancerous T-cells. By binding to CCR4, POTELIGEO attracts immune cells to destroy these malignant cells, enhancing the body's immune response against the cancer.

POTELIGEO was first approved in Japan in 2012 for treating relapsed or refractory CCR4-positive adult T-cell leukemia (ATL). In 2014, its approval was expanded in Japan to include relapsed or refractory CCR4-positive peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). The FDA approved POTELIGEO in 2018 for treating Mycosis Fungoides and Sezary Syndrome. It is also approved in Europe for these same conditions.

In June 2020, Kyowa Kirin announced the commercial availability of POTELIGEO in Germany for the treatment of adult patients with mycosis fungoides and Sezary syndrome who have received at least one prior systemic therapy.

AIMOVIG (erenumab-aooe): Novartis/Amgen

Erenumab is a fully human monoclonal antibody developed by Amgen and Novartis, which can specifically bind to CGRP receptors and is an antagonist that directly competes with CGRP ligands. CGRP ligands are small neuropeptides with potent vasodilating effects in the setting of chronic pain and migraine. When competing with CGRP, erenumab offers advantages over small molecule drugs in specificity and potency. The antibody is suitable for treating migraine, vasoconstriction, hot flashes, and stable angina pectoris. The monoclonal antibody was listed in the US and the EU in May and July 2018 respectively.

Emerging Drugs

Volagidemab: REMD Biotherapeutics

Volagidemab (REMD-477) is a human anti-glucagon receptor antibody developed by REMD Biotherapeutics against juvenile type I diabetes (T1D) and type II diabetes (T2D). It binds to the human GCGR and competitively blocks glucagon receptors (GCGR) signal transduction to increase liver glucose uptake, reduce liver glycogen decomposition and gluconeogenesis, and promote glycogen synthesis, to achieve the effect of hypoglycemia (CK060182). Up to March 2021, there were multiple experimental projects under development, of which, the research and development of type I and type II diabetes were in clinical stage II, the study on glucose intolerance was in clinical stage I and the study on metabolic disorders was in the preclinical stage (CK060183).

Leronlimab: CytoDyn

Leronlimab is a viral entry inhibitor, a class of HIV therapies that prevent the virus from entering and infecting healthy cells. Unlike Highly Active Antiretroviral Therapy (HAART), which targets the virus after it has entered the cell and begun replicating, Leronlimab acts earlier in the infection process. The importance of the CCR5 receptor in HIV is underscored by the natural resistance to HIV infection seen in individuals with a genetic mutation that prevents CCR5 expression. It is being developed for the treatment of Nonalcoholic Steatohepatitis (NASH), HIV-NASH, and solid tumors. Currently, it's in Phase II.

In April 2019, the Company entered into several agreements with Samsung, under which Samsung agreed to perform technology transfer, process validation, manufacturing, pre-approval inspection, and supply services for the commercial supply of leronlimab bulk drug substance.

GPCR-Targeting Therapies Market Outlook

The market for GPCR-Targeting therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing awareness of GPCR-Targeting therapies, and the increasing number of GPCR-Targeting therapies that are under clinical trials and filed for approval by various companies.

The market outlook for GPCR-targeting therapies is promising, driven by successful drugs like ZAVZPRET, POTELIGEO, AIMOVIG, and VYEPTI. Mogamulizumab, developed by Kyowa Hakko Kirin and marketed as POTELIGEO, targets the CCR4 receptor and has proven effective in treating CCR4-positive adult T-cell leukemia, peripheral T-cell lymphoma, and cutaneous T-cell lymphomas. AIMOVIG (erenumab), developed by Amgen and Novartis, targets the CGRP receptor and is used for migraines, vasoconstriction, hot flashes, and stable angina pectoris, showcasing the specificity and potency of GPCR-targeting therapies. VYEPTI is the FDA-approved IV treatment for migraine prevention.

Emerging therapies like Volagidemab and Leronlimab, GPC-100, and GSBR-1290 highlight the expanding potential of this market. Volagidemab, an anti-glucagon receptor antibody, is in Phase II trials for Type I and Type II diabetes, promoting hypoglycemia by blocking glucagon receptor signaling. Leronlimab, a viral entry inhibitor in Phase II development, targets the CCR5 receptor and is being developed for HIV, Nonalcoholic Steatohepatitis (NASH), HIV-NASH, and solid tumors. These advancements underline the significant therapeutic potential and market opportunities for GPCR-targeting drugs across various conditions.

Several key players, including CytoDyn, REMD Biotherapeutics, Structure Therapeutics, GPCR Therapeutics, and others, are involved in developing drugs for GPCR-Targeting therapies for various indications such as NASH, Multiple Myeloma, Diabetes, and others. Overall, this is an exciting new class of agents with great potential for development. The maturation of current studies over the next few years will lead to a better understanding of GPCR-Targeting therapies and define their role in the therapy of cancer.

GPCR-Targeting therapies Drugs Uptake

This section focuses on the uptake rate of potential approved and emerging GPCR-Targeting therapies expected to be launched in the market during 2024-2034.

GPCR-Targeting Therapies Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.

The presence of numerous drugs under different stages is expected to generate immense opportunity for GPCR-Targeting therapies market growth over the forecasted period.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for GPCR-Targeting therapies.

KOL Views

To keep up with current and future market trends, we take Industry Experts' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on GPCR-Targeting therapies' evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.

DelveInsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as Johns Hopkins Sidney Kimmel Cancer Center and others.

Their opinion helps understand and validate current and emerging therapy treatment patterns or GPCR-Targeting therapies market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.

In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

The abstract list is not exhaustive, will be provided in the final report

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of the GPCR-Targeting therapies, explaining its mechanism, and therapies (current and emerging).
• Comprehensive insight into the competitive landscape, and forecasts, the future growth potential of treatment rate, drug uptake, and drug information have been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current landscape.
• A detailed review of the GPCR-Targeting therapies market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis, expert insights/KOL views, and treatment preferences that help shape and drive the 7MM GPCR-Targeting therapies market.

GPCR-Targeting Therapies Report Insights

• GPCR-Targeting therapies Targeted Patient Pool
• Therapeutic Approaches
• GPCR-Targeting Therapies Pipeline Analysis
• GPCR-Targeting Therapies Market Size and Trends
• Existing and future Market Opportunity

GPCR-Targeting Therapies Report Key Strengths

• Eleven years Forecast
• The 7MM Coverage
• Key Cross Competition
• Drugs Uptake and Key Market Forecast Assumptions

GPCR-Targeting Therapies Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions:

• What was the GPCR-Targeting therapies' total market size, market share (%) distribution, and what would it look like in 2034? What are the contributing factors for this growth?
• Which drug is going to be the largest contributor in 2034?
• Which is the most lucrative market for GPCR-Targeting therapies?
• What are the pricing variations among different geographies for approved therapies?
• How the reimbursement landscape has for GPCR-Targeting therapies evolved since the first one was approved? Do patients have any access issues that are driven by reimbursement decisions?
• What are the risks, burdens, and unmet needs of treatment with GPCR-Targeting therapies? What will be the growth opportunities across the 7MM for the patient population of GPCR-Targeting therapies?
• What are the key factors hampering the growth of the GPCR-Targeting therapies market?
• What are the indications for which recent novel therapies and technologies have been developed to overcome the limitations of existing treatments?
• What key designations have been granted to the therapies for GPCR-Targeting therapies?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred therapy options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to buy:

• The report will help develop business strategies by understanding the latest trends and changing dynamics driving the GPCR-Targeting therapies Market.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of indication-wise current and emerging therapies under the conjoint analysis section to provide visibility around leading indications.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of GPCR-Targeting therapies

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. GPCR-Targeting therapies Market Overview at a Glance in the 7MM

• 6.1. Market Share (%) Distribution by Indication in 2020
• 6.2. Market Share (%) Distribution by Indication in 2034

7. GPCR-Targeting therapies: Background and Overview

8. Treatment and Management

9. Target Patient Pool

• 9.1 Key Findings
• 9.2 Assumptions and Rationale: 7MM
• 9.3 Epidemiology Scenario in the 7MM
  • 9.3.1 Total Cases of Selected Indication for GPCR-Targeting Therapies in the 7MM
  • 9.3.2 Total Eligible Patient Pool for GPCR-Targeting Therapies in Selected Indication in the 7MM
  • 9.3.3 Total Treatable Cases in Selected Indication for GPCR-Targeting Therapies in the 7MM

10. Marketed Therapies

• 10.1. Key Competitors
• 10.2. POTELIGEO (mogamulizumab-kpkc): Kyowa Hakko Kirin
  • 10.2.1. Product Description
  • 10.2.2. Regulatory milestones
  • 10.2.3. Other developmental activities
  • 10.2.4. Clinical development
  • 10.2.5. Safety and efficacy
• 10.3. AIMOVIG (erenumab-aooe): Novartis/Amgen
  • 10.3.1. Product Description
  • 10.3.2. Regulatory milestones
  • 10.3.3. Other developmental activities
  • 10.3.4. Clinical development
  • 10.3.5. Safety and efficacy

11. Emerging therapies

• 11.1. Key Competitors
• 11.2. Volagidemab: REMD Biotherapeutics
  • 11.2.1. Product Description
  • 11.2.2. Other developmental activities
  • 11.2.3. Clinical development
  • 11.2.4. Safety and efficacy
• 11.3. Leronlimab: CytoDyn
  • 11.3.1. Product Description
  • 11.3.2. Other developmental activities
  • 11.3.3. Clinical development
  • 11.3.4. Safety and efficacy

12. GPCR-Targeting Therapies: Seven Major Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Conjoint Analysis
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions and Rebates
  • 12.4.2. Pricing Trends
  • 12.4.3. Analogue Assessment
  • 12.4.4. Launch Year and Therapy Uptakes
• 12.5. Total Market Size by Indication in the 7MM
• 12.6. Total Market Size by Therapies in the 7MM
• 12.7. The United States
  • 12.7.1. Market Size by Indication in the United States
  • 12.7.2. Market Size by Therapies in the United States
• 12.8. EU4 and the UK
  • 12.8.1. Market Size by Indication in the EU4 and the UK
  • 12.6.2. Market Size by Therapies in the EU4 and the UK
• 12.9. Japan
  • 12.9.1. Market Size by Indication in Japan
  • 12.9.2. Market Size by therapies in Japan

13. KOL Views

14. Unmet Needs

15. Market Access and Reimbursement

16. Appendix

• 16.1. Bibliography
• 16.2. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight